1h Free Analyst Time
The exosome diagnostics and therapeutics market is forecasted to grow by USD 687.63 mn during 2023-2028, accelerating at a CAGR of 23.36% during the forecast period. The report on the exosome diagnostics and therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by raising research on exosome therapeutics, increasing demand for effective drugs for chronic diseases, and growing focus on early detection of cancer.
The exosome diagnostics and therapeutics market is segmented as below:
By Application
- Diagnostic
- Therapeutic
By End-user
- Research and academic institutes
- Pharmaceutical and biotechnology companies
- Commercial
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the exosome diagnostics and therapeutics market covers the following areas:
- Exosome diagnostics and therapeutics market sizing
- Exosome diagnostics and therapeutics market forecast
- Exosome diagnostics and therapeutics market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Application
7 Market Segmentation by End-user
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global exosome diagnostics and therapeutics market: Aethlon Medical Inc., Bio Techne Corp., BioCat GmbH, BioVision Inc., Capricor Therapeutics Inc., Cell Guidance Systems Ltd., Clara Biotech Inc., Evox Therapeutics Ltd., Hologic Inc., JSR Life Sciences LLC, Lonza Group Ltd., Merck KGaA, Miltenyi Biotec B.V. and Co. KG, Nanosomix Inc., NX PharmaGen Inc., QIAGEN NV, ReNeuron Group plc, Sarepta Therapeutics Inc, System Biosciences LLC, and Thermo Fisher Scientific Inc..Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is advanced technology in exosome collection.'
According to the report, one of the major drivers for this market is the rising research on exosome therapeutics.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aethlon Medical Inc.
- Bio Techne Corp.
- BioCat GmbH
- BioVision Inc.
- Capricor Therapeutics Inc.
- Cell Guidance Systems Ltd.
- Clara Biotech Inc.
- Evox Therapeutics Ltd.
- Hologic Inc.
- JSR Life Sciences LLC
- Lonza Group Ltd.
- Merck KGaA
- Miltenyi Biotec B.V. and Co. KG
- Nanosomix Inc.
- NX PharmaGen Inc.
- QIAGEN NV
- ReNeuron Group plc
- Sarepta Therapeutics Inc
- System Biosciences LLC
- Thermo Fisher Scientific Inc.